How is hexarelin dosed and mixed?
Draw to
unitsmL
0.3 mL · 30 units syringe0.5 mL · 50 units syringe1 mL · 100 units syringe3 mL · 3cc syringe0.5 mL · 20 units, U-40 syringe1 mL · 40 units, U-40 syringe
Concentration is the powder in the vial divided by the water. The draw is the dose divided by the concentration, in mL, times 100 on a U-100 syringe or 40 on a U-40. Every figure comes from what you enter.
Save to Milligram
Open in Milligram shows once the calculator has a result.
Open in Milligram is off while the dose is more than the whole vial. Check the dose and its unit.
Open in Milligram is off while the draw is under one unit. Check the dose and its unit.
Open in Milligram adds Hexarelin and this dose to a plan in the app, with the schedule you pick here. The vial and water are not saved.
The longest subcutaneous trial found, Rahim's, gave 16 weeks of twice-daily subcutaneous hexarelin at 1.5 micrograms/kg to 12 healthy elderly people; no hexarelin label turned up that gives a dose.12
The guide's example
200 mcg of Hexarelin from a 5 mg vial mixed with 2 mL is 8 units on a U-100 syringe.
Every vial at a glance. Pick a cell to draw it on the syringe.
| Vial | 1 mL of water | 2 mL of water |
|---|---|---|
| 2 mg | 2 mg/mL: 100 mcg is 5 units, 200 mcg is 10 units | 1 mg/mL: 100 mcg is 10 units, 200 mcg is 20 units |
| 5 mg | 5 mg/mL: 100 mcg is 2 units, 200 mcg is 4 units | 2.5 mg/mL: 100 mcg is 4 units, 200 mcg is 8 units |
Mixing hexarelin powder and reading the syringe
No hexarelin label or maker's leaflet turned up that gives a vial strength, or says which water to use and how much. The table above is arithmetic only: its vial sizes, water volumes and doses are worked examples, not figures from a label, a maker or a trial, and the injected trial doses below are given per kilogram of body weight.1
200 mcg of Hexarelin from a 5 mg vial mixed with 2 mL is 8 units on a U-100 syringe.
What human trials gave, by route
Ghigo's study of 12 healthy young volunteers gave hexarelin intravenously (1 and 2 micrograms/kg), subcutaneously (1.5 and 3 micrograms/kg), intranasally (20 micrograms/kg) and by mouth (20 and 40 mg).3 In Imbimbo's double-blind, placebo-controlled, rising-dose study, twelve adult male volunteers received single intravenous boluses of 0.5, 1 and 2 micrograms.kg-1 of hexarelin as well as placebo.4 None of the trial records searched states an injection site, only that the injections were subcutaneous.
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| Maccario5 | 1.5 microg/kg subcutaneously, two or three times daily, with a 1 microg/kg intravenous test dose at the end of each 24-h sampling | Six normal young men | One day of sampling |
| Rahim12 | 1.5 micrograms/kg subcutaneously, twice daily | 12 healthy elderly people | 16 weeks, checked 4 weeks after stopping |
| Laron6 | Intranasal 60 micrograms/kg three times daily | 8 prepubertal short children aged 4-11.6 years | Up to 8 months |
Schedule, cycle length and repeated use
None of the trial records searched states a cycle length for self-use; the longest subcutaneous trial found ran 16 weeks,1 and an intranasal trial in children ran up to 8 months.6 In Rahim's trial the GH response fell from 19.1 micrograms/L.h at week 0 to 10.5 at week 16, and was 19.4 at week 20 after stopping.1 The authors called this a partial and reversible attenuation of the GH response.1
Label, registry and sport status
A DailyMed search for hexarelin and examorelin returned no label. A ClinicalTrials.gov search for hexarelin, examorelin and EP-51389 returned no studies. The WADA 2026 Prohibited List names examorelin (hexarelin) among the GH-releasing peptides in section S2, prohibited at all times, in and out of competition.7 A review in Frontiers in Endocrinology states that in human studies hexarelin stimulates GH secretion and also raises prolactin, ACTH and cortisol.8 In Maccario's trial in six normal young men, two or three subcutaneous injections raised serum GH with no change in the secretion of prolactin, ACTH and cortisol, while an intravenous dose at the end of each sampling period raised all four.5
Forum cycles reported in a review
A review in Frontiers in Endocrinology reports that bodybuilding forums give 100-200 µg subcutaneously in one or two injections, with a typical cycle of 8-12 weeks on followed by 4 weeks off; these are forum figures, not trial results.8
Storage
No label or stability data for hexarelin turned up, before or after mixing. Vendor datasheets disagree with each other and cite no stability data, so no storage time is given here.
Frequently asked questions
What do Milligram users log for hexarelin?
No hexarelin figure from Milligram logs reaches the minimum needed to show one.
- HexarelinStudies, half-life and WADA status.
- Hexarelin calculatorMix and syringe arithmetic for other doses.
- Growth hormone peptidesThe class hexarelin belongs to.
- Mixing guideThe steps of reconstituting a vial.
- Tesamorelin dosageLabel and trial doses for tesamorelin.
- CJC-1295 and ipamorelin dosageDoses and mixing for the pair.
- HGH dosage in IUGrowth hormone doses in IU.
References
- PubMed. Growth hormone status during long-term hexarelin therapy. 1998. pubmed.ncbi.nlm.nih.gov
- PubMed. Does desensitization to hexarelin occur?. 1998. pubmed.ncbi.nlm.nih.gov
- PubMed. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man. 1994. pubmed.ncbi.nlm.nih.gov
- PubMed. Growth hormone-releasing activity of hexarelin in humans. A dose-response study. 1994. pubmed.ncbi.nlm.nih.gov
- PubMed. Impact of two or three daily subcutaneous injections of hexarelin, a synthetic growth hormone (GH) secretagogue, on 24-h GH, prolactin, adrenocorticotropin and cortisol secretion in humans. 2002. pubmed.ncbi.nlm.nih.gov
- PubMed. Intranasal administration of the GHRP hexarelin accelerates growth in short children. 1995. pubmed.ncbi.nlm.nih.gov
- WADA. WORLD ANTI-DOPING CODE. wada-ama.org
- Frontiers in Endocrinology. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. 2026. pmc.ncbi.nlm.nih.gov